Report date: After market close, Wednesday, August 5, 2026 · Call 4:30 p.m. ET Segments: MedSurg (Advanced Wound Care + Infection Prevention & Surgical Solutions), Dental Solutions, Health Information Systems (HIS)
This is not a normal quarter, and management has gone out of its way to tell investors so. To ease its largest and last big ERP cutover (U.S. and Canada, planned for Q3), Solventum is deliberately pulling orders forward — it guided to over $100 million of "advance-order" sales landing in Q2 that reverse in the second half, mostly in Q3. CFO Wayde McMillan's explicit advice on the Q1 call was blunt: don't model Q2 in isolation, because the pull-forward will make the quarter "substantially higher," and the company will simply mirror-image whatever the advance number turns out to be out of H2.
Practical implications going into the print: - A large reported/organic "beat" is highly likely — and largely mechanical. The signal to hunt for is the disclosed magnitude of the advance orders (above or below $100M) and the corresponding cut to H2/Q3, not the headline growth rate. - The full-year guide is the anchor. Management said repeatedly that nothing changes for FY26 regardless of the phasing. If the H2 offset is not fully taken out, that's a positive tell on underlying demand; if it is exactly offset, treat Q2 upside as timing. - The pull-forward mostly hits IP&SS and Dental (both heavily U.S. distribution-based), so those two lines will look artificially strong. - Incremental drop-through on the ~$100M is roughly ~30% to EPS, per management — so a chunky (but non-recurring) EPS tailwind is embedded too.
| Metric | Q2 FY25 (actual) | Consensus Q2 FY26 | Notes |
|---|---|---|---|
| Net sales (reported) | $2,161M (incl. P&F) | ~$2.17B (Zacks) | Not apples-to-apples: P&F was divested Sept 2025; Acera added Dec 2025 |
| Adj. diluted EPS | $1.69 | ~$1.91 (≈ +13% YoY) | SOLV has beaten in each of the last four quarters |
| Adj. operating margin | 21.9% | — | Q1'26 was 19.5% (seasonal low); expect sequential step-up |
| Adj. gross margin | 56.0% | — | Mgmt guided ~56%/just under 56% for remaining quarters |
Comparability caveats to flag in your model: the year-ago quarter still included ~$252M of Purification & Filtration revenue (now divested), while the current quarter carries Acera (contributed $28M in Q1) and an FX tailwind (~+100bps expected for the year). Reported growth will look negative; organic is the number that matters.
Solventum enters the print having affirmed FY26 on the Q1 call: - Organic sales +2.0% to +3.0% (+3.0% to +4.0% ex ~100bps of SKU-rationalization drag) - Adjusted EPS toward the high end of $6.40–$6.60 - Free cash flow ~$200M - Operating margin 21.0%–21.5% (+50–100bps YoY)
After a Q1 beat ($1.48 vs. ~$1.34 consensus) that pushed EPS to the high end, and with the Q2 pull-forward dropping ~30% through, the debate is whether management formally raises the EPS range (it has a history of raising through the year — it lifted FY25 guidance at both Q1 and Q2). A raise that is only the timing-related drop-through is lower quality than one driven by underlying demand or margins. Also watch FCF, which is heavily H2/Q4-weighted this year given step-down in separation costs.
Sentiment has turned decidedly bullish into the print, which raises the hurdle: - Shares closed at ~$88 (Aug 4), near a 52-week high of ~$88.21, up from the low-$60s in late March — a ~40% run in roughly four months. - The final leg was a UBS upgrade to Buy (PT $95) on July 28 that added ~7% in a day; Wedbush had earlier initiated at Outperform. Market cap ~$13.7B. - Net: the stock has re-rated on the "transformation is working / accelerating toward the 4–5% LRP" narrative. That leaves less room for error — a clean beat may be needed just to hold the level, and the quality of the Q2 print (given the timing distortions) will be scrutinized more than the headline.
Given the four-quarter beat streak and the embedded Q2 timing tailwind, a headline beat is the base case — but with the stock at highs, the reaction likely hinges on guidance and on how "clean" management makes the through-year bridge look.
Note: SOLV reports on a calendar-quarter basis (Q2 = quarter ended June 30, 2026). Figures above are non-GAAP/adjusted unless noted. Consensus figures are third-party estimates and may not reconcile precisely to the company's own definitions.